Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (688505)

Overview

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., established in 1996 and located in Shanghai, China, focuses on the development, production, and marketing of bio-pharmaceutical products. With a broad engagement in various stages of pharmaceutical development and manufacturing, the company has initiated a substantial presence within the Chinese healthcare sector. Its operations span across research and development, manufacture, sales of bio-pharmaceuticals, and even extends into medical diagnostics and technology consultation. The organization's commitment to innovation is fortified by its investment in advanced drug development platforms and participation in overseas medical projects.

Products and Services

The company's diverse portfolio leverages unique technological platforms for the development of its products:

• Genetic Engineering Platform Drugs:

  Includes a range of antibody-drug conjugates (ADCs) aimed at treating various tumor types. Notable examples are the CD30-DM1 ADC in Phase I clinical trials for tumors; the Trop2-SN38 ADC and Trop2-BB05 ADC targeting triple negative breast, bladder, gastric cancers, and lung cancer in Phase I and pre-clinical studies respectively; the DLL3-BB05 ADC for tumors in pre-clinical trials; and the HER2 ADC that has concluded Phase I clinical study for metastatic breast and gastric cancers.

• Photodynamic Technical Platform Drugs:

  Features drugs like hemoporfin for port wine stain in Phase IV clinical trial and aminolevulinic acid in Phase II clinical trials for cervical diseases infected by HPV, acne, and a completed pre-clinical study for brain gliomas.

• Nano Technical Platform Drugs:

  Encompasses Doxorubicin liposome development for tumor treatments.

• Oral Solid Preparation Technology:

  This segment includes drugs such as obeticholic acid for hepatobiliary and autoimmune diseases; timolol maleate cream in Phase I clinical trials for infantile hemangioma; and FZJ-003 oral preparation, in clinical trials for rheumatoid arthritis, atopic dermatitis, and ulcerative colitis.

In addition to these pharmaceutical innovations, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. offers medical diagnostic products and related services, sells daily necessities and clinical laboratory analysis instruments and software. The company is also actively involved in technology development, transfer, consulting, and promotional activities. It further specializes in the production of freeze-dried powder injections and active pharmaceutical ingredients (APIs), contributing significantly to both domestic and international medical projects.